These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22272687)

  • 1. Paradoxical and bidirectional drug effects.
    Smith SW; Hauben M; Aronson JK
    Drug Saf; 2012 Mar; 35(3):173-89. PubMed ID: 22272687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical adverse drug reactions: descriptive analysis of French reports.
    Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods.
    Coelho MM; Fernandes C; Remião F; Tiritan ME
    Molecules; 2021 May; 26(11):. PubMed ID: 34070985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to "The link between pharmacodynamics and physiologically based pharmacokinetic models".
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2013 Feb; 93(2):152. PubMed ID: 23281422
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic studies in pregnancy.
    Avram MJ
    Semin Perinatol; 2020 Apr; 44(3):151227. PubMed ID: 32093881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The link between pharmacodynamics and physiologically based pharmacokinetic models.
    Perera V; Elmeliegy MA; Rao G; Forrest A
    Clin Pharmacol Ther; 2013 Feb; 93(2):151-2. PubMed ID: 23299648
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.
    Strandell J; Wahlin S
    Eur J Clin Pharmacol; 2011 Jun; 67(6):633-41. PubMed ID: 21253716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental Changes in Pharmacokinetics and Pharmacodynamics.
    van den Anker J; Reed MD; Allegaert K; Kearns GL
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S10-S25. PubMed ID: 30248190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Academic Detailing from the Viewpoint of Chemical Structural Formulas].
    Wada T
    Yakugaku Zasshi; 2019; 139(8):1101-1105. PubMed ID: 31366846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system.
    Chen CJ; Cheng CF; Lin HY; Hung SP; Chen WC; Lin MS
    J Clin Pharm Ther; 2012 Dec; 37(6):647-51. PubMed ID: 22646235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.
    Chen ML
    Clin Pharmacokinet; 2006; 45(10):957-64. PubMed ID: 16984210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic crisis in the elderly.
    ElDesoky ES
    Am J Ther; 2007; 14(5):488-98. PubMed ID: 17890940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis.
    Kunac DL; Tatley MV
    Drug Saf; 2011 Jan; 34(1):59-71. PubMed ID: 21142271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to "Physiologically based pharmacokinetic modeling at the extremes of age".
    Della Casa Alberighi O; Barrett JS; Läer S; Meibohm B
    Clin Pharmacol Ther; 2013 Feb; 93(2):149. PubMed ID: 23187875
    [No Abstract]   [Full Text] [Related]  

  • 20. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
    Bennett CL; Schooley B; Taylor MA; Witherspoon BJ; Godwin A; Vemula J; Ausdenmoore HC; Sartor O; Yang YT; Armitage JO; Hrushesky WJ; Restaino J; Thomsen HS; Yarnold PR; Young T; Knopf KB; Chen B
    PLoS One; 2019; 14(7):e0219521. PubMed ID: 31365527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.